Alnylam Pharmaceuticals/$ALNY
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Alnylam Pharmaceuticals
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.
Ticker
$ALNY
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
2,230
ISIN
US02043Q1076
Website
ALNY Metrics
BasicAdvanced
$38B
-
-$2.10
0.30
-
Price and volume
Market cap
$38B
Beta
0.3
52-week high
$300.90
52-week low
$146.79
Average daily volume
926K
Financial strength
Current ratio
3.038
Quick ratio
2.836
Long term debt to equity
2,247.54
Total debt to equity
2,358.255
Interest coverage (TTM)
-0.79%
Management effectiveness
Return on assets (TTM)
-1.79%
Return on equity (TTM)
519.47%
Valuation
Price to revenue (TTM)
15.88
Price to book
327.49
Price to tangible book (TTM)
327.49
Price to free cash flow (TTM)
-494.637
Growth
Revenue change (TTM)
17.21%
Earnings per share change (TTM)
-20.76%
3-year revenue growth (CAGR)
38.70%
3-year earnings per share growth (CAGR)
-34.57%
What the Analysts think about ALNY
Analyst ratings (Buy, Hold, Sell) for Alnylam Pharmaceuticals stock.
ALNY Financial Performance
Revenues and expenses
ALNY Earnings Performance
Company profitability
ALNY News
AllArticlesVideos
AMVUTTRA® (vutrisiran) Significantly Reduces Mortality and a Range of Important Cardiovascular Events in Patients with ATTR Amyloidosis with Cardiomyopathy: Additional Data from HELIOS-B
Business Wire·2 weeks ago
Alnylam Pharmaceuticals, Inc. (ALNY) Q1 2025 Earnings Call Transcript
Seeking Alpha·4 weeks ago
Alnylam Receives Positive CHMP Opinion for Vutrisiran for the Treatment of ATTR Amyloidosis with Cardiomyopathy
Business Wire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Alnylam Pharmaceuticals stock?
Alnylam Pharmaceuticals (ALNY) has a market cap of $38B as of May 29, 2025.
What is the P/E ratio for Alnylam Pharmaceuticals stock?
The price to earnings (P/E) ratio for Alnylam Pharmaceuticals (ALNY) stock is 0 as of May 29, 2025.
Does Alnylam Pharmaceuticals stock pay dividends?
No, Alnylam Pharmaceuticals (ALNY) stock does not pay dividends to its shareholders as of May 29, 2025.
When is the next Alnylam Pharmaceuticals dividend payment date?
Alnylam Pharmaceuticals (ALNY) stock does not pay dividends to its shareholders.
What is the beta indicator for Alnylam Pharmaceuticals?
Alnylam Pharmaceuticals (ALNY) has a beta rating of 0.3. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.